Peringatan Keamanan

Symptoms of overdose include convulsions, nausea, and vomiting.

Ethionamide

DB00609

small molecule approved

Deskripsi

A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)

Struktur Molekul 2D

Berat 166.243
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2 to 3 hours
Volume Distribusi * 93.5 L [healthy volunteers]
Klirens (Clearance) -

Absorpsi

Essentially completely absorbed following oral administration and not subjected to any appreciable first pass metabolism. Bioavailability approximately 100%.

Metabolisme

Hepatic and extensive. Metabolized to the active metabolite sulfoxide, and several inactive metabolites. The sulphoxide metabolite has been demonstrated to have antimicrobial activity against Mycobacterium tuberculosis.

Rute Eliminasi

Less than 1% of the oral dose is excreted as ethionamide in urine. Ethionamide is extensively metabolized to active and inactive metabolites.

Interaksi Makanan

1 Data
  • 1. Take with or without food. Taking Ethionamide with food may reduce gastrointestinal upset.

Interaksi Obat

84 Data
Cycloserine The risk or severity of adverse effects can be increased when Ethionamide is combined with Cycloserine.
Isoniazid The serum concentration of Isoniazid can be increased when it is combined with Ethionamide.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ethionamide.
Ethanol The risk or severity of adverse effects can be increased when Ethanol is combined with Ethionamide.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ethionamide.
Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ethionamide.
Dicoumarol The risk or severity of bleeding can be increased when Ethionamide is combined with Dicoumarol.
Phenindione The risk or severity of bleeding can be increased when Ethionamide is combined with Phenindione.
Warfarin The risk or severity of bleeding can be increased when Ethionamide is combined with Warfarin.
Phenprocoumon The risk or severity of bleeding can be increased when Ethionamide is combined with Phenprocoumon.
Acenocoumarol The risk or severity of bleeding can be increased when Ethionamide is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Ethionamide is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Ethionamide is combined with Coumarin.
(R)-warfarin The risk or severity of bleeding can be increased when Ethionamide is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Ethionamide is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of bleeding can be increased when Ethionamide is combined with Fluindione.
Clorindione The risk or severity of bleeding can be increased when Ethionamide is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Ethionamide is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding can be increased when Ethionamide is combined with Tioclomarol.
(S)-Warfarin The risk or severity of bleeding can be increased when Ethionamide is combined with (S)-Warfarin.
Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Ethionamide.
Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ethionamide.
Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ethionamide.
Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Ethionamide.
Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ethionamide.
Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Ethionamide.
Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ethionamide.
Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ethionamide.
Methimazole The therapeutic efficacy of Methimazole can be decreased when used in combination with Ethionamide.
Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Ethionamide.
3,5-Diiodotyrosine The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Ethionamide.
Tiratricol The therapeutic efficacy of Tiratricol can be decreased when used in combination with Ethionamide.
Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ethionamide.
Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ethionamide.
Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Ethionamide.
Dibromotyrosine The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Ethionamide.
Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ethionamide.
Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Ethionamide.
Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Ethionamide.
3,5-diiodothyropropionic acid The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Ethionamide.
Methylthiouracil The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Ethionamide.
Elcatonin The therapeutic efficacy of Elcatonin can be decreased when used in combination with Ethionamide.
Benzylthiouracil The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Ethionamide.
Thyrotropin The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Ethionamide.
Magnesium The serum concentration of Magnesium can be decreased when it is combined with Ethionamide.
Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ethionamide.
Bacillus calmette-guerin substrain russian BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Ethionamide.
Estetrol The therapeutic efficacy of Estetrol can be decreased when used in combination with Ethionamide.
Lidocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Quinisocaine.
Cisatracurium Ethionamide may increase the neuromuscular blocking activities of Cisatracurium.
Ambroxol The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Ambroxol.
Fecal microbiota The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Ethionamide.
Palopegteriparatide The therapeutic efficacy of Palopegteriparatide can be decreased when used in combination with Ethionamide.

Target Protein

Enoyl-[acyl-carrier-protein] reductase [NADH] inhA
Nuclear factor erythroid 2-related factor 2 NFE2L2
Catalase-peroxidase katG

Referensi & Sumber

Synthesis reference: Chimie et Atomistique, France: British Patent 800,250: August 20, 1958.

Contoh Produk & Brand

Produk: 1 • International brands: 11
Produk
  • Trecator
    Tablet, film coated • 250 mg/1 • Oral • US • Approved
International Brands
  • Ethatyl — Sanofi
  • Ethide — Lupin
  • Ethiokox — Radicura
  • Ethomid — Vesalius Pharma
  • Etionamida — AC Farma
  • Etomid — Macleods
  • Eton — Umeda
  • Etyomid — Koçak
  • Myobid — Panacea
  • Trecator-SC

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul